Article Versions Notes

Ryu J-S, Sim SH, Park IH, Lee EG, Lee ES, Kim Y-H, Kwon Y, Kong S-Y, Lee KS. Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer. Cancers. 2019; 11(4):574. https://doi.org/10.3390/cancers11040574

Ryu, Jin-Sun, Sung Hoon Sim, In Hae Park, Eun Gyeong Lee, Eun Sook Lee, Yun-Hee Kim, Youngmee Kwon, Sun-Young Kong, and Keun Seok Lee. 2019. "Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer" Cancers 11, no. 4: 574. https://doi.org/10.3390/cancers11040574

Ryu, J.-S., Sim, S. H., Park, I. H., Lee, E. G., Lee, E. S., Kim, Y.-H., Kwon, Y., Kong, S.-Y., & Lee, K. S. (2019). Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer. Cancers, 11(4), 574. https://doi.org/10.3390/cancers11040574